ZYDELIG® efficacy

Demonstrated efficacy in single-agent and combination studies

Select an indication to view efficacy or explore ZYDELIG’s mechanism of action

Relapsed follicular lymphoma

Relapsed follicular lymphoma (FL) in patients who have received at least two prior systemic therapies

Relapsed CLL

Relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities

Relapsed SLL

Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies

Mechanism of action

ZYDELIG is the first oral PI3Kδ inhibitor approved in both relapsed/refractory follicular lymphoma and relapsed CLL

FL and SLL are approved based on overall response rate. Improvement in patient survival or disease-related symptoms has not been established. Continued approval for these indications may be contingent upon verification of clinical benefit in confirmatory trials.

ZYDELIG is not indicated or recommended for first-line treatment of any patient or in combination with bendamustine and/or rituximab for the treatment of FL.

PI3Kδ=phosphatidylinositol 3-kinase delta.

Reference:

  1. ZYDELIG® (idelalisib) [Prescribing Information]. Foster City, CA: Gilead Sciences, Inc.; rev October 2020.